Similarly, in BRAF mutant cancers, combined inhibition of BRAF with other members of the MAP kinase family, such as MAPK1-MAPK3 and MAP2K1-MAP2K2, overcomes emergent mechanisms of resistance [7]. Here, BRAF is linked to cancer.